LogicBio Therapeutics (LOGC) to Announce Quarterly Earnings on Thursday

LogicBio Therapeutics (OTCMKTS:LOGC) is projected to issue its Q2 2026 resultson Thursday, August 6th. Analysts expect LogicBio Therapeutics to announce earnings of ($0.0414) per share and revenue of $22.4760 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

LogicBio Therapeutics Stock Down 0.5%

LOGC stock opened at $9.40 on Thursday. The stock has a 50-day simple moving average of $9.13 and a two-hundred day simple moving average of $8.51. LogicBio Therapeutics has a twelve month low of $7.05 and a twelve month high of $10.35. The firm has a market capitalization of $429.91 million, a PE ratio of -8.62 and a beta of 2.01. The company has a quick ratio of 1.15, a current ratio of 1.67 and a debt-to-equity ratio of 0.28.

Hedge Funds Weigh In On LogicBio Therapeutics

An institutional investor recently raised its stake in LogicBio Therapeutics stock. Goldman Sachs Group Inc. increased its position in shares of LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) by 284.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 526,673 shares of the company’s stock after acquiring an additional 389,843 shares during the period. Goldman Sachs Group Inc. owned approximately 2.00% of LogicBio Therapeutics worth $3,676,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 46.05% of the company’s stock.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics, Inc, a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia.